FindTrial
Sign In

A multicentre, multinational, double blind, randomised, parallel group, placebo-controlled study of ethyl-eicosapentaenoate (EPA) in patients with Huntington's disease (HD)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN79170611
Enrollment
Unknown
Registered
2003-02-03
Start date
2003-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Huntington's disease Nervous System Diseases Huntington's disease

Interventions

Two groups randomly allocated to placebo or 2 g/day ethyl EPA on a double blind basis. Patients who completed the 12 month randomisation phase of the trial were invited to take part in a further 12 m

Sponsors

Laxdale Ltd (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Availability of a responsible family member or carer to look after the patient during the trial and ensure complete compliance 3. Diagnosis of HD in stage I

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026